title: How best to address these common movement disorders.
authors.affiliation: Antalya Training and Research Hospital, Neurology Clinic, Antalya, Turkey.
authors.forename: Aylin
authors.initials: A
authors.lastname: Yaman
authors.forename: Melahat
authors.initials: M
authors.lastname: Akdeniz
authors.forename: Hakan
authors.initials: H
authors.lastname: Yaman
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D020329:Essential Tremor / Q000188:drug therapy; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology; D010300:Parkinson Disease / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D011324:Primidone / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D013747:Tetrabenazine / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000319:Adrenergic beta-Antagonists; D000927:Anticonvulsants; D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D011324:Primidone; D007980:Levodopa; D011433:Propranolol; D013747:Tetrabenazine